Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
1.880
-0.070 (-3.59%)
Jan 21, 2025, 4:00 PM EST - Market closed
Climb Bio Employees
As of December 31, 2023, Climb Bio had 11 total employees, including 9 full-time and 2 part-time employees. The number of employees decreased by 32 or -74.42% compared to the previous year.
Employees
11
Change (1Y)
-32
Growth (1Y)
-74.42%
Revenue / Employee
n/a
Profits / Employee
-$6,283,818
Market Cap
126.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 11 | -32 | -74.42% |
| Dec 31, 2022 | 43 | 12 | 38.71% |
| Dec 31, 2021 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
CLYM News
- 12 days ago - Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy - GlobeNewsWire
- 4 weeks ago - Climb Bio to be Added to the Nasdaq Biotechnology Index - GlobeNewsWire
- 2 months ago - Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 2 months ago - Climb Bio Appoints Douglas E. Williams, Ph.D. - GlobeNewsWire
- 3 months ago - Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event - GlobeNewsWire
- 3 months ago - Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024 - GlobeNewsWire
- 3 months ago - Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19 - GlobeNewsWire
- 3 months ago - Climb Bio to Host Virtual Investor Event on October 15, 2024 - GlobeNewsWire